JP2022121359A - シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト - Google Patents

シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト Download PDF

Info

Publication number
JP2022121359A
JP2022121359A JP2021131089A JP2021131089A JP2022121359A JP 2022121359 A JP2022121359 A JP 2022121359A JP 2021131089 A JP2021131089 A JP 2021131089A JP 2021131089 A JP2021131089 A JP 2021131089A JP 2022121359 A JP2022121359 A JP 2022121359A
Authority
JP
Japan
Prior art keywords
thr
synaptic
loss
ser
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021131089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022121359A5 (https=
Inventor
アール． ラフ マイケル
R Ruff Michael
ロスナー ギラ
Rosner Gilah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Bio Peptides Inc
Original Assignee
Creative Bio Peptides Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Bio Peptides Inc filed Critical Creative Bio Peptides Inc
Publication of JP2022121359A publication Critical patent/JP2022121359A/ja
Publication of JP2022121359A5 publication Critical patent/JP2022121359A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021131089A 2020-02-06 2021-08-11 シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト Pending JP2022121359A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970869P 2020-02-06 2020-02-06
US17/170,790 US20210244788A1 (en) 2020-02-06 2021-02-08 Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
US17/170,790 2021-02-08

Publications (2)

Publication Number Publication Date
JP2022121359A true JP2022121359A (ja) 2022-08-19
JP2022121359A5 JP2022121359A5 (https=) 2024-09-04

Family

ID=77178645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021131089A Pending JP2022121359A (ja) 2020-02-06 2021-08-11 シナプスおよび樹状突起棘の喪失を逆転させるための複数のケモカインレセプターの経口用ペプチドアンタゴニスト

Country Status (3)

Country Link
US (2) US20210244788A1 (https=)
JP (1) JP2022121359A (https=)
CN (1) CN114903990A (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116990520A (zh) * 2022-04-25 2023-11-03 中国科学院深圳先进技术研究院 一种蛋白棒状体标志物及其应用
WO2025124536A1 (zh) * 2023-12-15 2025-06-19 江苏康缘药业股份有限公司 趋化因子受体8拮抗多肽化合物、组合物、试剂盒及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322252A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
WO2020018315A2 (en) * 2017-07-18 2020-01-23 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567682A (en) * 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
AU2006261133B2 (en) * 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
WO2019135995A1 (en) * 2018-01-02 2019-07-11 Rush University Medical Center Compositions and methods for treating neurological disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140322252A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
WO2020018315A2 (en) * 2017-07-18 2020-01-23 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Inhibiting inflammation with CCR2/5 antagonist reverses mechanical and cold allodynia in painful dia", SOCIETY FOR NEUROSCIENCE [ONLINE], vol. Program#/Poster#: 166.01/NN17, JPN6025035724, 10 November 2013 (2013-11-10), ISSN: 0005675402 *
NEUROCHEM INT, vol. 119, JPN6025035723, 2018, pages 184 - 189, ISSN: 0005675403 *
PAIN, vol. 153, JPN6025035725, 2012, pages 95 - 106, ISSN: 0005675401 *

Also Published As

Publication number Publication date
US20210244788A1 (en) 2021-08-12
US20240238363A1 (en) 2024-07-18
CN114903990A (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
DE60031792T2 (de) Schimärische amyloid-beta peptide
US20240238363A1 (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
CN101361961B (zh) 多肽小分子在制备防治缺血性脑血管病药物中的应用
JPH07509721A (ja) 組織形成因子誘導による神経の再生と修復
WO1996040095A1 (en) Method for treating multiple sclerosis
JP2010504083A5 (https=)
JP2021075550A (ja) グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物
US6090775A (en) Treatment of neurological conditions by an interleukin-1 inhibiting compound
US9149509B2 (en) Methods for improving neurological outcome after neural injury and neurodegenerative disease
JP5219168B2 (ja) アルツハイマー病の予防および／または治療用βシート破壊ペプチド
EP2991664B1 (de) Agenzien zur prävention und therapie von folgeerkrankungen von hiv und anderer viraler infektionen
DE69932834T2 (de) Neue Peptide
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
DE4413938A1 (de) Peptide als Therapeutikum für Autoimmunerkrankungen
EP4039264A1 (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
HK40079377A (en) Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines
Shao et al. Promotion of axon regeneration and inhibition of astrocyte activation by alpha A-crystallin on crushed optic nerve
CN1278184A (zh) 预防或治疗局部缺血性疾病的药剂
CN111991553B (zh) 一种治疗神经损伤性疼痛的药物及其应用
US20180066027A1 (en) Protamine in treatment of neuronal injuries
EP0839048A1 (en) Method of treating epilepsy with brain derived neurotrophic factor
US8318660B2 (en) Method of treating a disease by administering caspase-8
WO2022077823A1 (zh) 甲氧喹酸在制备用于治疗和/或预防以t-型钙通道为治疗靶点的疾病的药物中的应用
WO2011021832A2 (ko) 척수 손상 예방 또는 치료용 조성물
WO2007092799A2 (en) Method for promoting myocardial regeneration and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240809

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260302